依达拉奉右莰醇联合阿加曲班治疗急性脑梗死的临床效果  

Clinical effect of edaravone dexborneol combined with argatroban in the treatment of acute cerebral infarction

作　　者：吕昌迎 LYU Changying(DepartmentⅢof Brain Disease,Jinan Integrated Traditional Chinese and Western Medicine Hospital,Jinan 271100,China)

机构地区：[1]济南市中西医结合医院脑病三科,271100

出　　处：《临床合理用药杂志》2024年第22期9-12,共4页Chinese Journal of Clinical Rational Drug Use

基　　金：山东省中医药科技青年项目(Q-2022003)。

摘　　要：目的 观察依达拉奉右莰醇联合阿加曲班治疗急性脑梗死(ACI)的临床效果。方法 选取2021年1月—2022年12月济南市中西医结合医院收治的ACI患者86例,按随机数字表法分为观察组和对照组各43例。对照组予以阿加曲班治疗,观察组在对照组基础上加用依达拉奉右莰醇治疗,2组均治疗7 d。比较2组临床疗效,治疗前后美国国立卫生研究院卒中量表(NIHSS)评分、炎性因子[超敏C反应蛋白(hs-CRP)、白介素-6(IL-6)及肿瘤坏死因子-α(TNF-α)]水平、氧化应激反应指标[丙二醛(MDA)、谷胱甘肽过氧化物酶(GSH-Px)、超氧化物歧化酶(SOD)]、大脑中动脉血流速度[收缩期峰值血流速度(Vs)、舒张期末血流速度(Vd)和平均血流速度(Vm)]及不良反应。结果 观察组总有效率为95.35%,高于对照组的81.40%(χ^(2)=4.074,P=0.044);治疗7 d后,2组NIHSS评分及hs-CRP、IL-6、TNF-α、MDA水平低于治疗前,GSH-Px、SOD水平高于治疗前,大脑中动脉Vs、Vd、Vm快于治疗前,且观察组变化幅度大于对照组(P<0.01);观察组与对照组不良反应总发生率比较差异无统计学意义(11.63%vs.6.98%,χ^(2)=0.138,P=0.711)。结论 依达拉奉右莰醇联合阿加曲班可增强ACI治疗效果,减轻炎性反应及氧化应激反应,增加脑血流灌注,保护神经功能,且安全性高。Objective To observe the clinical effect of edaravone dexborneol combined with argatroban in the treatment of acute cerebral infarction(ACI).Methods Eighty-six patients with ACI admitted to Jinan Integrated Traditional Chinese and Western Medicine Hospital from January 2021 to December 2022 were selected,and they were divided into the observation group and the control group according to the random number table method,43 cases in each group.The control group was treated with argatroban,and the observation group was treated with edaravone dexborneol on the basis of the control group,both groups were treated for 7 days.The clinical efficacy,and the NIHSS score,inflammatory factors(hs-CRP,IL-6 and TNF-α),oxidative stress indicators(SOD,GSH-Px,MDA),middle cerebral artery blood flow velocity(Vs,Vd,Vd)before and after treatment,and adverse effects were compared between the two groups.Results The total effective rate of the observation group was 95.35%,which was higher than 81.40% of the control group(χ^(2)=4.074,P=0.044).After 7 days of treatment,NIHSS score and hs-CRP,IL-6,TNF-α,MDA levels of the two groups were lower than those before treatment,GSH-Px,SOD levels were higher than those before treatment,and the middle cerebral artery Vs,Vd,and Vm were faster than those before treatment,and the magnitude of change in the observation group was greater than that in the control group(P<0.01).The difference in the total incidence of adverse reactions between the observation group and the control group was not statistically significant(11.63% vs.6.98%,χ^(2)=0.138,P=0.711).Conclusion Edaravone dexborneol combined with argatroban can enhance the therapeutic effect of ACI,reduce inflammation and oxidative stress response,increase cerebral blood perfusion,protect neurological function,and have high safety.

关 键 词：急性脑梗死 依达拉奉右莰醇 阿加曲班 炎性因子 氧化应激反应 

分 类 号：R743.33[医药卫生—神经病学与精神病学]